Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.

التفاصيل البيبلوغرافية
العنوان:	Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
المؤلفون:	Ares-Gómez S; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Mallah N; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Department of Preventive Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain., Pardo-Seco J; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Genética de Poblaciones en Biomedicina (GenPoB) Research Group, Instituto de Investigación Sanitaria (IDIS), 15706 Hospital Clínico Universitario de Santiago (SERGAS), Santiago de Compostela, Galicia, Spain., Malvar-Pintos A; Department of Epidemiology, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Pérez-Martínez O; Department of Epidemiology, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Otero-Barrós MT; Department of Epidemiology, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Súarez-Gaiche N; Department of Epidemiology, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Santiago-Pérez MI; Department of Epidemiology, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., González-Pérez JM; Subdirección de Sistemas y Tecnologías de la Información, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., López-Pérez LR; Subdirección de Sistemas y Tecnologías de la Información, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Rosón B; Subdirección de Sistemas y Tecnologías de la Información, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Alvárez-Gil RM; Deparment of Communicable Diseases, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Ces-Ozores OM; Deparment of Communicable Diseases, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Nartallo-Penas V; Deparment of Communicable Diseases, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Mirás-Carballal S; Deparment of Communicable Diseases, Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Rodríguez-Tenreiro C; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Rivero-Calle I; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Salas A; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Genética de Poblaciones en Biomedicina (GenPoB) Research Group, Instituto de Investigación Sanitaria (IDIS), 15706 Hospital Clínico Universitario de Santiago (SERGAS), Santiago de Compostela, Galicia, Spain.; Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain., Durán-Parrondo C; Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, Galicia, Spain., Martinón-Torres F; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
المصدر:	Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology [Pediatr Allergy Immunol] 2024 May; Vol. 35 (5), pp. e14131.
نوع المنشور:	Journal Article; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: Blackwell Publishing Country of Publication: England NLM ID: 9106718 Publication Model: Print Cited Medium: Internet ISSN: 1399-3038 (Electronic) Linking ISSN: 09056157 NLM ISO Abbreviation: Pediatr Allergy Immunol Subsets: MEDLINE
أسماء مطبوعة:	Publication: <2010->: Oxford, UK : Blackwell Publishing Original Publication: Copenhagen : Munksgaard, c1990-
مواضيع طبية MeSH:	Respiratory Syncytial Virus Infections/epidemiology , Primary Health Care/statistics & numerical data , Hospitalization*/statistics & numerical data, Humans ; Infant ; Male ; Female ; Longitudinal Studies ; Spain/epidemiology ; Infant, Newborn ; Incidence ; Respiratory Syncytial Virus, Human ; Morbidity ; Cost of Illness
مستخلص:	Background: The morbidity burden of respiratory syncytial virus (RSV) in infants extends beyond hospitalization. Defining the RSV burden before implementing prophylaxis programs is essential for evaluating any potential impact on short- to mid-term morbidity and the utilization of primary healthcare (PHC) and emergency services (ES). We established this reference data using a population-based cohort approach. Methods: Infants hospitalized for RSV from January 2016 to March 2023 were matched with non-hospitalized ones based on birthdate and sex. We defined the exposure as severe RSV hospitalization. The main study outcomes were as follows: (1) PHC and ES visits for RSV, categorized using the International Classification of Primary Care codes, (2) prescriptions for respiratory airway obstructive disease, and (3) antibacterial prescriptions. Participants were followed up from 30 days before hospitalization for severe RSV until the outcome occurrence or end of the study. Adjusted incidence rate ratios (IRRs) of the outcomes along with their 95% confidence intervals (CI) were estimated using Poisson regression models. Stratified analyses by type of PHC visit (nurse, pediatrician, or pharmacy) and follow-up period were undertaken. We defined mid-term outcomes as those taking place up to 24 months of follow-up period. Results: The study included 6626 children (3313 RSV-hospitalized; 3313 non-hospitalized) with a median follow-up of 53.7 months (IQR = 27.9, 69.4). After a 3-month follow-up, severe RSV was associated with a considerable increase in PHC visits for wheezing/asthma (IRR = 4.31, 95% CI: 3.84-4.84), lower respiratory infections (IRR = 4.91, 95% CI: 4.34-5.58), and bronchiolitis (IRR = 4.68, 95% CI: 2.93-7.65). Severe RSV was also associated with more PHC visits for the pediatrician (IRR = 2.00, 95% CI: 1.96-2.05), nurse (IRR = 1.89, 95% CI: 1.75-1.92), hospital emergency (IRR = 2.39, 95% CI: 2.17-2.63), primary healthcare emergency (IRR: 1.54, 95% CI: 1.31-1.82), as well as with important increase in prescriptions for obstructive airway diseases (IRR = 5.98, 95% CI: 5.43-6.60) and antibacterials (IRR = 4.02, 95% CI: 3.38-4.81). All findings remained substantial until 2 years of post-infection. Conclusions: Severe RSV infection in infants significantly increases short- to mid-term respiratory morbidity leading to an escalation in healthcare utilization (PHC/ES attendance) and medication prescriptions for up to 2 years afterward. Our approach could be useful in assessing the impact and cost-effectiveness of RSV prevention programs. (© 2024 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
References:	Gil‐Prieto R, Gonzalez‐Escalada A, Marin‐Garcia P, Gallardo‐Pino C, Gil‐de‐Miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore). 2015;94(21):e831. doi:10.1097/MD.0000000000000831. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946‐958. doi:10.1016/S0140-6736(17)30938-8. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047‐2064. doi:10.1016/S0140-6736(22)00478-0. Del Riccio M, Spreeuwenberg P, Osei‐Yeboah R, et al. Burden of respiratory syncytial virus in the European Union: estimation of RSV‐associated hospitalizations in children under 5 years. J Infect Dis. 2023;228(11):1528‐1538. doi:10.1093/infdis/jiad188. Gea‐Izquierdo E, Gil‐Prieto R, Hernandez‐Barrera V, Gil‐de‐Miguel A. Respiratory syncytial virus‐associated hospitalization in children aged <2 years in Spain from 2018 to 2021. Hum Vaccin Immunother. 2023;19(2):2231818. doi:10.1080/21645515.2023.2231818. Viguria N, Martinez‐Baz I, Moreno‐Galarraga L, Sierrasesumaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS One. 2018;13(11):e0206474. doi:10.1371/journal.pone.0206474. Martinon‐Torres F, Carmo M, Platero L, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759. doi:10.1186/s12879-022-07745-0. Diez‐Domingo J, Perez‐Yarza EG, Melero JA, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544. doi:10.1186/s12879-014-0544-x. Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91‐100 e103. doi:10.1016/j.jaci.2012.02.010. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J. 2003;22(2 Suppl):S6‐S10; discussion S10‐12. doi:10.1097/01.inf.0000053880.92496.db. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791‐1799. doi:10.1056/NEJMoa1211917. Simoes EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180‐189. doi:10.1016/S2352-4642(22)00321-2. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451‐1464. doi:10.1056/NEJMoa2216480. Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425‐2435. doi:10.1056/NEJMoa2309189. Martinon‐Torres F, Miras‐Carballal S, Duran‐Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long‐acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28(49):pii=2300606. doi:10.2807/1560-7917.ES.2023.28.49.2300606. Galician Health Service [Servizo Galego de Saude]. Lifetime immunization schedule [Calendario de inmunización ao longo de toda a vida]. 2023. Accessed January 10, 2023. https://www.sergas.es/Saude‐publica/Calendario‐comun‐vacinacion. Martinon‐Torres F, Navarro‐Alonso JA, Garces‐Sanchez M, Soriano‐Arandes A. The path towards effective respiratory syncytial virus immunization policies: recommended actions. Arch Bronconeumol. 2023;59(9):581‐588. doi:10.1016/j.arbres.2023.06.006. Galician Health Service [Servizo Galego de Saúde]. Epidemiological Bulletin of Galicia volume XXXII, number 6. Circulation of the respiratory syncytial virus in Galicia: Validity of the wave threshold. [Boletín Epidemiolóxico de Galicia volume XXXII, número 6. Circulación do virus respiratorio sincitial en Galicia: validez do limiar de onda.]. 2023. Accessed January 10, 2023. https://www.sergas.gal/Saude‐publica/BEG‐Volume‐XXXII. Galician Statistical Institute [Instituto Galego de Estadística]. Accessed January 10, 2023. https://www.ige.gal/. Galician Health Service [Servizo Galego de Saúde]. Healthy Child Program [Programa Neno San/Niño Sano – Revisiones / Revisións pediatra]. 2023. Accessed January 10, 2023. https://www.interseccion.es/programa‐neno‐san‐nino‐sano‐revisiones‐revisions‐pediatra/. WONCA International Classification Committee [Comité Internacional de Clasificación de la WONCA]. Clasificación Internacional de la Atención Primaria segunda edición. CIAP ‐ 2. WONCA International Classification Committee; 1999. Zeileis A, Köll S, Graham N. Various versatile variances: an object‐oriented implementation of clustered Covariances in R. J Stat Softw. 2020;95(1):1‐36. doi:10.18637/jss.v095.i01. Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related health care utilization in the United States. J Glob Health. 2020;10(2):020422. doi:10.7189/jogh.10.020422. Munoz‐Quiles C, Lopez‐Lacort M, Ubeda‐Sansano I, et al. Population‐based analysis of bronchiolitis epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275‐280. doi:10.1097/INF.0000000000000993. Homaira N, Briggs N, Pardy C, et al. Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high‐risk Australian children: a whole‐of‐population‐based cohort study. BMJ Open. 2017;7(11):e017936. doi:10.1136/bmjopen-2017-017936. Homaira N, Briggs N, Oei JL, et al. Association of age at first severe respiratory syncytial virus disease with subsequent risk of severe asthma: a population‐based cohort study. J Infect Dis. 2019;220(4):550‐556. doi:10.1093/infdis/jiy671. Szabo SM, Levy AR, Gooch KL, Bradt P, Wijaya H, Mitchell I. Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev. 2013;13(Suppl 2):S9‐S15. doi:10.1016/S1526-0542(12)70161-6. Turi KN, Shankar J, Anderson LJ, et al. Infant viral respiratory infection nasal immune‐response patterns and their association with subsequent childhood recurrent wheeze. Am J Respir Crit Care Med. 2018;198(8):1064‐1073. doi:10.1164/rccm.201711-2348OC. Andrade MA, Hoberman A, Glustein J, Paradise JL, Wald ER. Acute otitis media in children with bronchiolitis. Pediatrics. 1998;101(4 Pt 1):617‐619. doi:10.1542/peds.101.4.617. Smith CB, Golden C, Klauber MR, Kanner R, Renzetti A. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis. 1976;134(6):552‐561. doi:10.1093/infdis/134.6.552. de Steenhuijsen Piters WA, Heinonen S, Hasrat R, et al. Nasopharyngeal microbiota, host transcriptome, and disease severity in children with respiratory syncytial virus infection. Am J Respir Crit Care Med. 2016;194(9):1104‐1115. doi:10.1164/rccm.201602-0220OC. Morpeth SC, Munywoki P, Hammitt LL, et al. Impact of viral upper respiratory tract infection on the concentration of nasopharyngeal pneumococcal carriage among Kenyan children. Sci Rep. 2018;8(1):11030. doi:10.1038/s41598-018-29119-w. Lukens MV, van de Pol AC, Coenjaerts FE, et al. A systemic neutrophil response precedes robust CD8(+) T‐cell activation during natural respiratory syncytial virus infection in infants. J Virol. 2010;84(5):2374‐2383. doi:10.1128/JVI.01807-09. Thwaites RS, Coates M, Ito K, et al. Reduced nasal viral load and IFN responses in infants with respiratory syncytial virus bronchiolitis and respiratory failure. Am J Respir Crit Care Med. 2018;198(8):1074‐1084. doi:10.1164/rccm.201712-2567OC. Sande CJ, Njunge JM, Mwongeli Ngoi J, et al. Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019;10(1):2218. doi:10.1038/s41467-019-10222-z. Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Natl Acad Sci USA. 2022;119(12):e2112410119. doi:10.1073/pnas.2112410119. Fauroux B, Simoes EAF, Checchia PA, et al. The burden and long‐term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173‐197. doi:10.1007/s40121-017-0151-4.
معلومات مُعتمدة:	Instituto de Salud Carlos III; Sanofi; Axencia Galega de Innovación; European Regional Development Fund; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
فهرسة مساهمة:	Keywords: Spain; asthma; hospitalizations; infants; primary healthcare; respiratory syncytial virus; viral bronchiolitis
تواريخ الأحداث:	Date Created: 20240503 Date Completed: 20240503 Latest Revision: 20240503
رمز التحديث:	20240503
DOI:	10.1111/pai.14131
PMID:	38700124
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	1399-3038
DOI:	10.1111/pai.14131